TENORMIN Drug Patent Profile

When do Tenormin patents expire, and what generic alternatives are available?

Tenormin is a drug marketed by Astrazeneca and Twi Pharms and is included in two NDAs.

The generic ingredient in TENORMIN is atenolol. There are thirty-four drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the atenolol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenormin

A generic version of TENORMIN was approved as atenolol by AIPING PHARM INC on July 15^th, 1988.

Summary for TENORMIN

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	125
Clinical Trials:	16
Patent Applications:	4,108
Drug Prices:	Drug price information for TENORMIN
What excipients (inactive ingredients) are in TENORMIN?	TENORMIN excipients list
DailyMed Link:	TENORMIN at DailyMed

See drug prices for TENORMIN

Recent Clinical Trials for TENORMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
High Risk Obstetrical Consultants	Early Phase 1
University of Tennessee Medical Center	Early Phase 1
University of Tennessee Graduate School of Medicine	Early Phase 1

See all TENORMIN clinical trials

Pharmacology for TENORMIN

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TENORMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	TENORMIN	atenolol	INJECTABLE;INJECTION	019058-001	Sep 13, 1989		DISCN	Yes	No
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-004	Apr 9, 1990	AB	RX	Yes	No

Expired US Patents for TENORMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-001	Approved Prior to Jan 1, 1982
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-002	Approved Prior to Jan 1, 1982
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-004	Apr 9, 1990

International Patents for TENORMIN

See the table below for patents covering TENORMIN around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	37458
Spain	376788
Hungary	164914

TENORMIN (atenolol): Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is TENORMIN’s market position and how has it shifted over time?

TENORMIN is the brand of atenolol, a beta-1 selective blocker used primarily for hypertension, angina, and post-myocardial infarction management. While atenolol has remained a widely prescribed therapy class, TENORMIN’s commercial trajectory has been constrained by the shift from brand exclusivity to generic competition.

Market dynamic:

• Brand-to-generic transition: After patent expiry in key jurisdictions, atenolol’s market became dominated by multiples of low-cost generics, compressing unit price and limiting sustained brand revenue.
• Therapeutic durability without brand economics: Demand for beta-blockers persists due to established clinical roles, but the brand captures less of that demand once generics proliferate.

Competitive context:

• TENORMIN competes in the antihypertensive and cardiovascular prevention space with both:
  • Other beta-blockers (e.g., metoprolol, bisoprolol, propranolol derivatives depending on jurisdiction and indication),
  • Alternative first-line or guideline-positioned drug classes (ACE inhibitors/ARBs, calcium channel blockers, diuretics, and in selected settings newer agents).

How do price erosion and generic substitution drive TENORMIN’s revenue trajectory?

The financial arc for TENORMIN is largely explained by two interlocking forces: (1) generic substitution and (2) ongoing prescriber switching to lower acquisition cost products once available.

Key economic mechanism:

• Generic entry reduces brand net sales through substitution, not through demand destruction.
• Net price declines faster than volume gains, since generics set the market clearing price and payers steer prescribing.

What this implies for financial trajectory:

• TENORMIN’s revenue growth, where it exists, generally comes from:
  • Geographic pockets with slower generic penetration,
  • Brand retention in specific formularies or prescriber preferences,
  • Substitution resistance for certain strengths or package formats (limited effect once generics fully match the formulary).

In practice, for legacy cardiovascular brands like TENORMIN, the typical pattern is:

• Early stability during exclusivity,
• Flat-to-declining revenue post-entry of multiples of generic products,
• Gradual downshift in brand share even when total class demand remains steady.

How has TENORMIN performed versus the broader beta-blocker market?

From a market-structure standpoint, beta-blockers have remained a mature therapeutic category. For TENORMIN, the distinction is not whether patients need beta-blockade, but whether the prescribing is attached to the brand.

Relative performance drivers:

• Guideline alignment: Beta-blockers remain used across chronic cardiovascular indications, supporting baseline demand.
• Patent and reimbursement reality: The brand’s ability to monetize that demand is reduced once payer formularies and pharmacy benefits promote generics.
• Switching behavior: Clinician confidence in generics and substitution at the pharmacy level accelerates post-expiry revenue decline.

What are the key demand drivers for atenolol that can support baseline volume?

Even with brand pressure, the class has stable usage because atenolol’s indications align with common clinical pathways.

Core demand inputs:

• Hypertension treatment: Long-standing beta-blocker use, though guideline positioning varies by geography and patient profile.
• Angina: Beta-blockers remain a mainstay option.
• Post-myocardial infarction risk management: Beta-blockade is embedded in secondary prevention strategies.

Supply-side demand stability:

• Atenolol is widely available in multiple generic forms, which reduces supply risk to patients and maintains treatment continuity.

How do regulatory and product-level factors affect TENORMIN’s market?

Brand beta-blocker products can be affected by:

• Formulation and strength availability (tablet strength, dosing convenience),
• Manufacturing approvals and label changes (safety communications can alter prescribing behavior),
• Market access at payer level (preferred drug lists, prior authorization rules in some formularies).

TENORMIN’s competitive situation is less about technical differentiation and more about access economics once generics are available.

Financial trajectory: what direction does the money move post-genericization?

TENORMIN’s financial trajectory follows the standard legacy brand pattern in mature, patent-expired cardiovascular markets:

Revenue direction (typical pattern for atenolol brands):

• Decline after genericization due to net price erosion and share loss.
• Possible short-term stabilizations tied to formulary contracts or reduced generic competition in a given market segment, but these usually do not reverse long-run substitution trends.

Margin dynamics:

• Gross margin pressure rises as:
  • Brand must cut price to retain share,
  • Commercial cost-to-serve stays relatively fixed while revenue contracts.

Net effect:

• Brand earnings trajectory tends toward:
  • Lower sales,
  • Reduced profitability as the brand competes primarily on price rather than differentiated clinical value.

Where does TENORMIN sit within AstraZeneca’s portfolio economics?

TENORMIN is associated with the AstraZeneca brand portfolio historically (atenolol is a legacy cardiovascular asset within the AstraZeneca lineage). For large pharma portfolios, legacy cardiovascular brands typically become:

• Reduced contributors to consolidated growth,
• Cash-generators early, then declining contributors post-expiry,
• Managed for life-cycle value rather than expansion.

This portfolio reality reinforces why TENORMIN’s financial trajectory is dominated by market access and pricing outcomes rather than R&D-led upside.

What market-level signals matter for investors and operators tracking TENORMIN?

Investors and operators generally focus less on clinical efficacy and more on market-structure indicators:

Commercial monitoring set:

1. Generic count and launch timing in key markets (multiplicity predicts faster price erosion).
2. Formulary status changes and preferred pricing tiers (drives pharmacy substitution).
3. Net price trends rather than list price (captures payer rebates and contract dynamics).
4. Demand stability for the beta-blocker class as a check on whether volume is protecting revenue.

Is there any meaningful upside left for TENORMIN as a brand?

Upside exists only where payer or pharmacy behavior sustains brand share despite generic availability. Practical upside levers are:

• Locked-in formulary contracts for brand versions in some institutions,
• Brand continuity for specific dosing regimens when substitution is delayed,
• Localized supply constraints affecting generics (rare, usually temporary).

In the long-run, without a differentiated product, brand economics remain tethered to generic penetration.

How does TENORMIN’s market dynamics compare with typical cardiovascular incumbents?

TENORMIN’s behavior matches a common profile among mature cardiovascular brands:

• High baseline need because indications are entrenched.
• Low brand leverage once patents expire.
• Persistent substitution driven by reimbursement economics.

Where brand equity still matters, it typically shows up in institutional prescribing inertia or payer friction against switching. Over time, friction reduces as generics become standard.

Key Takeaways

• TENORMIN’s market position is anchored to persistent clinical use of atenolol, but its brand economics are dominated by generic substitution and payer-driven price erosion.
• The financial trajectory is structurally biased toward declining net sales and margin compression post-generic entry, with only limited, geography- and formulary-specific stabilization.
• Monitoring should focus on generic launch multiplicity, formulary status, net price trends, and class-level demand since these variables drive revenue more than incremental clinical differentiation.

FAQs

1) What drives TENORMIN’s revenue more: volume or price?

Net price typically drives revenue more strongly once generics enter because payers and pharmacies steer prescribing toward the lowest-cost option even if overall beta-blocker use stays stable.

2) Does persistent hypertension prevalence prevent TENORMIN’s brand decline?

It can preserve total class demand, but it does not prevent brand-specific decline once generics capture most prescriptions through substitution and reimbursement economics.

3) What are the main competitors to TENORMIN?

Other beta-blockers (e.g., metoprolol, bisoprolol) and other antihypertensive cardiovascular drug classes depending on guideline position and patient profile.

4) What is the most reliable indicator of future TENORMIN net sales?

The rate of generic penetration and changes in formulary tiering, because these directly determine substitution speed and payer net pricing.

5) Is there a path for sustained brand monetization for TENORMIN?

Sustained monetization is mainly possible through contract-specific formulary retention or delayed substitution in targeted markets; durable upside generally requires differentiation, which is limited for an established, non-innovative generic-comparable molecule.

References

[1] FDA. DailyMed: Tenormin (atenolol) label information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
[2] EMA. EPAR and product information resources for atenolol-containing medicines. European Medicines Agency. https://www.ema.europa.eu/
[3] AstraZeneca. Company and product history materials referencing legacy cardiovascular brands. AstraZeneca corporate site. https://www.astrazeneca.com/